1. Home
  2. SAVA vs BDL Comparison

SAVA vs BDL Comparison

Compare SAVA & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAVA
  • BDL
  • Stock Information
  • Founded
  • SAVA 1998
  • BDL 1959
  • Country
  • SAVA United States
  • BDL United States
  • Employees
  • SAVA N/A
  • BDL N/A
  • Industry
  • SAVA Biotechnology: Pharmaceutical Preparations
  • BDL Restaurants
  • Sector
  • SAVA Health Care
  • BDL Consumer Discretionary
  • Exchange
  • SAVA Nasdaq
  • BDL Nasdaq
  • Market Cap
  • SAVA 70.5M
  • BDL 60.8M
  • IPO Year
  • SAVA N/A
  • BDL N/A
  • Fundamental
  • Price
  • SAVA $1.99
  • BDL $29.00
  • Analyst Decision
  • SAVA Buy
  • BDL
  • Analyst Count
  • SAVA 3
  • BDL 0
  • Target Price
  • SAVA $54.50
  • BDL N/A
  • AVG Volume (30 Days)
  • SAVA 1.1M
  • BDL 3.3K
  • Earning Date
  • SAVA 08-07-2025
  • BDL 08-12-2025
  • Dividend Yield
  • SAVA N/A
  • BDL 1.67%
  • EPS Growth
  • SAVA N/A
  • BDL 14.76
  • EPS
  • SAVA N/A
  • BDL 2.18
  • Revenue
  • SAVA N/A
  • BDL $198,785,000.00
  • Revenue This Year
  • SAVA N/A
  • BDL N/A
  • Revenue Next Year
  • SAVA N/A
  • BDL N/A
  • P/E Ratio
  • SAVA N/A
  • BDL $15.93
  • Revenue Growth
  • SAVA N/A
  • BDL 9.31
  • 52 Week Low
  • SAVA $1.15
  • BDL $22.61
  • 52 Week High
  • SAVA $42.20
  • BDL $35.98
  • Technical
  • Relative Strength Index (RSI)
  • SAVA 51.90
  • BDL 45.79
  • Support Level
  • SAVA $1.76
  • BDL $30.11
  • Resistance Level
  • SAVA $2.17
  • BDL $35.18
  • Average True Range (ATR)
  • SAVA 0.10
  • BDL 1.08
  • MACD
  • SAVA -0.02
  • BDL -0.36
  • Stochastic Oscillator
  • SAVA 55.95
  • BDL 0.00

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

About BDL Flanigan's Enterprises Inc.

Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.

Share on Social Networks: